←back to Blog

Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study

Breast Cancer Res Treat. 2026 Nov 16;220(2):42. doi: 10.1007/s10549-026-08126-w.

ABSTRACT

BACKGROUND: HR+/HER2- breast cancer is the most prevalent molecular subtype of breast cancer, yet overall pathological complete response (pCR) rates after neoadjuvant chemotherapy remain low. BRCA mutations and homologous recombination deficiency (HRD) may sensitize tumors to PARP inhibitors through synthetic lethality. We investigated the efficacy and safety of fluzoparib combined with neoadjuvant chemotherapy in patients with HRD-positive and/or germline BRCA (gBRCA)-mutated HR+/HER2- early breast cancer.

PATIENTS AND METHODS: This single-center, prospective, open-label, single-arm phase II trial (NCT07162051) enrolled women aged 18-70 years with newly diagnosed HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer. Patients received fluzoparib combined with docetaxel during cycles 1-4, followed by epirubicin plus cyclophosphamide during cycles 5-8. The primary endpoint was the proportion of patients achieving residual cancer burden (RCB) grade 0/I. Secondary endpoints included objective response rate (ORR), pathological complete response (pCR) rate, and safety.

RESULTS: Twenty-eight patients were enrolled between March 2023 and October 2025. Four patients (14.3%; 95% CI 4.0%-32.7%) achieved RCB 0/I, two patients (7.1%; 95% CI 0.9%-23.5%) achieved total pCR (tpCR), and six patients (21.4%; 95% CI 8.3%-41.0%) achieved breast pCR (bpCR). The ORR was 82.1%. Grade 3-4 treatment-related adverse events occurred in four patients (14.3%). No treatment discontinuations, dose reductions, treatment delays, or treatment-related deaths were observed.

CONCLUSIONS: The addition of fluzoparib to standard neoadjuvant chemotherapy did not improve RCB 0/I rates in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer, although the regimen was well tolerated. Future studies should focus on gBRCA-mutated or higher-risk populations and explore optimized combination strategies, including anti-angiogenic agents. REGISTRATION CENTER, TRIAL REGISTRATION NUMBER, AND REGISTRATION DATE: This is a prospective, open label, single arm phase II clinical trial. Registry: ClinicalTrials.gov; Trial registration number: NCT07162051; Registration date:2023-02-21.

PMID:43037769 | DOI:10.1007/s10549-026-08126-w